Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%.
- DEMESNE RESOURCES LTD. ANNOUNCES CLOSING OF A SECOND TRANCHE OF PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT FINANCING - December 13, 2024
- Lochmere Association Wins 2024 Associa Green Award - December 13, 2024
- Front Range Pharmacy Expands Innovative Services to Enhance Healthcare in Denver - December 13, 2024